Compare TPVG & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPVG | ADAG |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2M | 146.3M |
| IPO Year | 2013 | 2020 |
| Metric | TPVG | ADAG |
|---|---|---|
| Price | $5.20 | $4.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $6.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 633.4K | 315.5K |
| Earning Date | 05-06-2026 | 04-01-2026 |
| Dividend Yield | ★ 18.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.67 | $3,688.61 |
| Revenue Next Year | N/A | $17.39 |
| P/E Ratio | $4.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.48 | $1.34 |
| 52 Week High | $7.53 | $4.72 |
| Indicator | TPVG | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 56.47 |
| Support Level | $5.14 | $1.69 |
| Resistance Level | $5.39 | $4.58 |
| Average True Range (ATR) | 0.23 | 0.48 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 75.82 | 49.23 |
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.